A Phase 1/2 interventional study of Talabostat and Pembrolizumab in Prostate Cancer, Neuroendocrine Tumors and Small Cell Carcinoma, sponsored by BioXcel Therapeutics Inc. Completed at 12 sites in 2 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by BioXcel Therapeutics Inc · Phase 1/2, Interventional, and Treatment
How we know · 11 judgments · one reading being read again
Phase 1B: Talabostat 0.4 mg QD + Pembrolizumab 200 mg · Phase 1B: Talabostat 0.6 mg QD + Pembrolizumab 200 mg · Phase 1B: Talabostat 0.6 mg TDD + Pembrolizumab 200 mg · Phase 2A (SCNC): Talabostat + Pembrolizumab 200 mg · Phase 2A (Adenocarcinoma): Talabostat + Pembrolizumab 200 mg · Phase 2B (Adenocarcinoma): Talabostat + Pembrolizumab 200 mg
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 3,597 studies in Prostatic Neoplasms with a site in United States — 605 open to participants now, 974 under way, 100 of them phase 3. Prostatic Neoplasms · United States.
Among the 3,597 studies in Prostatic Neoplasms with a site in United States, this one is the 970th largest by enrollment of the 3,024 interventional ones that give a count, is one of 160 that started in 2019, is one of 284 in phase 1/2, and was the 2,331st registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →605 of the 3,597 studies in Prostatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:
University of Miami · Sites in United States
Ages 18–80 · Men only
City of Hope Medical Center · Sites in United States
Ages 40–80 · Men only
Fred Hutchinson Cancer Center · Sites in United States
Ages 18+ · Men only
University of Michigan Rogel Cancer Center · Sites in United States
Ages 50–75 · Men only · Healthy volunteers
University of California, San Diego · Sites in United States
Ages 18+ · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
3,597 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 899 · Phase 2 1,384 · Phase 3 321 · Phase 4 50
First in 1988; this study’s year is marked. 160 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 97 is above the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 48 across the 3,024 interventional studies, 158 across the 478 observational. Of the 2,360 that completed or were terminated, 997 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
922 of 3,597 have an industry lead sponsor. The 10 most frequent:
BioXcel Therapeutics Inc is the lead sponsor of 15 studies on the registry; 1 is open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 9 (75%) have results posted.
BioXcel Therapeutics Inc has 1 study filed under Prostatic Neoplasms — fewer than ten, so there is no comparison to draw.
334 of the studies in Prostatic Neoplasms with a site in United States that are under way reach primary completion within a year, 24 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03767244Phase 3Janssen Research & Development, LLCA Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy | 2026-12-01 |
| NCT06970847Phase 3Clarity Pharmaceuticals Ltd64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer | 2026-12-31 |
| NCT02446405Phase 3University of SydneyEnzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer | 2026-12-31 |
| NCT07427043Phase 3Brigham and Women's HospitalRobotic Opioid-free Prostatectomy Enhanced Strategy (ROPES) | 2026-12-31 |
| NCT04691804Phase 3Jiangsu HengRui Medicine Co., Ltd.A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer | 2026-12-31 |
Add all 334 to your calendar (.ics) → With an account.
Among the 3,597 studies in Prostatic Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
An open-label, multicenter, Phase 1b/2 study to identify the recommended Phase 2 dose and assess the efficacy and safety of talabostat administered orally, as monotherapy and in combination with pembrolizumab, in participants with mCRPC. Participants enrolled in the Phase 2a portion of the study will have either SCNC (Cohort A) or adenocarcinoma phenotype (Cohort B), while the Phase 2b randomized portion of the study will enroll only the histologic subtype(s) showing preliminary evidence in Phase 2a. The study will also assess other efficacy parameters, such as radiographic progression-free survival (rPFS), prostate-specific antigen progression-free survival (PSA PFS), overall survival (OS), and duration of response (DOR), as well as the safety of the combined treatment.
The study will consist of three components.
Phase 2a (Simon 2 Stage): Participants will be treated with talabostat in combination with pembrolizumab. Participants will be grouped in 1 of 2 cohorts based on phenotype.
Phase 2b (for the histologic subtype[s] showing preliminary efficacy in Phase 2a): Participants within a given subtype will be randomized 2:1 to receive either talabostat combined with pembrolizumab or talabostat monotherapy.
Phase 1b:
Participants will be observed for dose-limiting toxicity (DLT) during Cycle 1. Three participants will be treated initially with talabostat 0.4 mg plus pembrolizumab:
If ≥1 of the 3 original participants has a DLT in Cycle 1, after a discussion between the sponsor and the investigator, either 3 participants (if 1 participant experiences a DLT) or 6 to 9 participants (if 2 or 3 participants experiences a DLT) will be added at the 0.4 mg talabostat dose level. For this expanded 0.4 mg cohort:
Following dose escalation to talabostat 0.6 mg plus pembrolizumab in 3 participants :
For this additional cohort of 6 to 9 participants :
The criteria were revised on the registry on Nov 10, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All participants must satisfy the following inclusion and exclusion criteria to be eligible for entry into the trial.
Participant has evidence of progressive, castration-resistant disease, as defined by Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria.
a. Participant with de novo small cell prostate cancer are not required to have received androgen deprivation therapy (ADT).
Phases 2a and 2b Only:
SCNC - Cohort A of Phase 2a only:
Adenocarcinoma - Cohort B of Phase 2a; randomized population for Phase 2b
Participant has serum testosterone \<50 ng/dL during Screening except for those with de novo small cell prostate cancer.
a. Participants with treatment-emergent SCNC without a history of bilateral orchiectomy are required to remain on luteinizing hormone-releasing hormone (LHRH) analog during the course of protocol therapy except for participants with de novo small cell prostate cancer.
Participant has adequate baseline organ function, as demonstrated by the following:
Participant has adequate baseline hematologic function, as demonstrated by the following:
Male participants and their female partners of must agree and commit to use a barrier throughout the duration of the study until at least 6 months following the last dose of study drug, in addition to their female partners using either an intrauterine device or hormonal contraception and continuing until at least 6 months following the last dose of study drug. This criterion may be waived for male participants who have had a vasectomy >6 months before signing the form.
Exception: In the United States, female partners of study participants are not required to use contraception as a condition of their partners' eligibility, but female partners with childbearing potential should consider use of effect methods of contraception for the duration of their male partners' study participation and for at least 6 months following the last dose of study medication.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive the combination of talabostat 0.4 mg QD orally on Days 1 to 14 of a 21-day cycle plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle. There will be a 7-day rest period following the last dose of talabostat and Day 1 of the subsequent cycle.
Drug: Talabostat · Drug: Pembrolizumab
Participants will receive the combination of talabostat 0.6 mg QD orally on Days 1 to 14 of a 21-day cycle plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle. There will be a 7-day rest period following the last dose of talabostat and Day 1 of the subsequent cycle.
Drug: Talabostat · Drug: Pembrolizumab
Participants will receive the combination of talabostat 0.3 mg twice daily (BID) (at a total daily dose \[TDD\] of 0.6 mg) orally on Days 1 to 14 of a 21-day cycle plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle. There will be a 7-day rest period following the last dose of talabostat and Day 1 of the subsequent cycle.
Drug: Talabostat · Drug: Pembrolizumab
Participants with SCNC will receive the combination of talabostat 0.6 mg QD orally on Days 1 to 14 a 21-day cycle plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle. There will be a 7-day rest period following the last dose of talabostat and Day 1 of the subsequent cycle.
Drug: Talabostat · Drug: Pembrolizumab
Participants with adenocarcinoma will receive the combination of talabostat 0.6 mg QD orally on Days 1 to 14 a 21-day cycle plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle. There will be a 7-day rest period following the last dose of talabostat and Day 1 of the subsequent cycle.
Drug: Talabostat · Drug: Pembrolizumab
Participants with adenocarcinoma will receive the combination of talabostat 0.6 mg QD orally on Days 1 to 14 a 21-day cycle plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle. There will be a 7-day rest period following the last dose of talabostat and Day 1 of the subsequent cycle.
Drug: Talabostat · Drug: Pembrolizumab
Participants with adenocarcinoma will receive talabostat 0.6 mg QD orally on Days 1 to 14 a 21-day cycle. There will be a 7-day rest period following the last dose of talabostat and Day 1 of the subsequent cycle.
Drug: Talabostat
Oral Tablets
Also known as: BXCL701
Intravenous injection
Phase 2a: Composite Response Rate (CRR)
CRR was defined as the percentage of participants who achieved 1 or more of the following: objective response by Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) criteria; ≥50% decline from baseline in serum Prostate-Specific Antigen (PSA); or Circulating Tumor Cell (CTC) conversion from ≥5/7.5 milliliters (mL) to \<5/7.5 mL per Veridex assay. Objective response rate was defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) among participants with evaluable lesions by RECIST v1.1. CR=disappearance of all target and non-target lesions and no new lesions. PR = ≥30% decrease in the sum of diameters (SOD) of target lesions compared to baseline and no new non-target lesion.
Time frame: Up to approximately 4 years and 4 months
Phase 2b: Objective Response Rate (ORR)
The ORR was defined as the percentage of participants with a confirmed CR or PR among participants with evaluable lesions by RECIST v1.1. CR=disappearance of all target and non-target lesions and no new lesions. PR = ≥30% decrease in the sum of the diameters of target lesions compared to baseline and no new non-target lesion.
Time frame: Up to approximately 4 years and 4 months
Phase 2a: Radiographic Progression-free Survival (rPFS)
The rPFS was defined as the time from the first dose to the date measurement criteria are first met for disease progression (PD) by RECIST 1.1/Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria or death from any cause, whichever occurred first. PD for soft tissue was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on study, including baseline, and an absolute increase of at least 5 millimeters (mm) in the SOD of target lesions; progression of non-target lesions; the appearance of one or more new lesions according to RECIST v1.1. PD for bone lesions was defined as 2 or more new lesions compared to baseline followed by a confirmatory bone scan at least 6 weeks later according to the PCWG3 criteria. Kaplan-Meier (KM) estimate was used to determine the median rPFS.
Time frame: Up to approximately 6 years 2 months
Phase 2a: Prostate Specific Antigen (PSA) Progression-free Survival (PFS)
The PSA PFS was defined as the time from the date of first dose to the date measurement criteria were first met for PSA progression by PCWG3 criteria or death from any cause, whichever occurred first. PSA progression was defined as a PSA increase that was ≥ 25% and ≥ 2 nanograms (ng)/mL above the baseline or the nadir, which was confirmed by a second value ≥ 3 weeks later. KM estimate was used to determine the median PSA PFS.
Time frame: Up to approximately 6 years and 2 months
Phase 2a: Overall Survival (OS)
The OS was defined as the difference in days between the date of death and the first date of study treatment (+1 day).
Time frame: Up to approximately 6 years and 2 months
Phase 2a: Duration of Response (DOR)
The DOR was defined as the time from the first objective response (CR or PR) to the first documented PD per RECIST v1.1 or death from any cause, whichever occurred first. CR was defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm. PR was defined as at least 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters. PD: at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: Up to approximately 6 years and 2 months
Phase 2a: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) was any untoward medical occurrence in a participant participating in a clinical investigation, whether or not considered related to treatment. A TEAE was defined as an AE occurring on / after the date of first dose of talabostat/pembrolizumab and within 30 days of the last dose of talabostat/pembrolizumab..
Time frame: From first dose of study drug up to approximately 6 years and 2 months
Phase 2a: ≥50% Decline in PSA Value From Baseline (PSA50) Duration of Response (PSA50 DOR)
The PSA50 DOR was defined as the time interval between the first date when PSA declined 50% or more from baseline and the date on which PSA progression was confirmed or death from any cause, whichever occurred first. PSA progression by PCWG3 criteria was defined as a PSA increase that was ≥ 25% and ≥ 2 ng/mL above the baseline or the nadir.
Time frame: Up to approximately 6 years and 2 months
Phase 2a: Duration of Stable Disease
Duration of stable disease by RECIST v1.1 was defined as the time interval between the first date when the criteria for stable disease were met and the first date on which objective progression was documented or death from any cause, whichever occurs first. Objective progression: at least a 20% increase in the SOD of target lesion. Stable disease was defined as \<30% decrease and \<20% increase in the size of target lesions, persistence of non-target lesions, and no new lesions.
Time frame: Up to approximately 6 years and 2 months
Phase 2b: Number of Participants With PSA Decline From Baseline of at Least 50%
Time frame: Up to approximately 6 years and 2 months
Phase 2b: CRR
CRR was defined as the percentage of participants who achieved 1 or more of the following: objective response by RECIST v1.1 criteria; ≥50% decline from baseline in serum PSA, or CTC conversion from ≥5/7.5 mL to \<5/7.5 mL per Veridex assay. Objective response rate was defined as the percentage of participants with a confirmed CR or PR among participants with evaluable lesions by RECIST v1.1. CR=disappearance of all target and non-target lesions and no new lesions. PR = ≥30% decrease in the SOD of target lesions compared to baseline and no new non-target lesion.
Time frame: Up to approximately 6 years and 2 months
Phase 2b: rPFS
The rPFS was defined as the time from the first dose to the date measurement criteria were first met for PD by RECIST 1.1/PCWG3 criteria or death from any cause, whichever occurred first. PD for soft tissue was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on study, including baseline, and an absolute increase of at least 5 mm in the SOD of target lesions; progression of non-target lesions; the appearance of one or more new lesions according to RECIST v1.1. PD for bone lesions was defined as 2 or more new lesions compared to baseline followed by a confirmatory bone scan at least 6 weeks later according to the PCWG3 criteria. KM estimate was used to determine the median rPFS.
Time frame: Up to approximately 6 years and 2 months
Phase 2b: PSA PFS
The PSA PFS was defined as the time from the date of first dose to the date measurement criteria were first met for PSA progression by PCWG3 criteria or death from any cause, whichever occurred first. PSA progression was defined as a PSA increase that was ≥ 25% and ≥ 2 ng/mL above the baseline or the nadir. KM estimate was used to determine the median PSA PFS.
Time frame: Up to approximately 6 years and 2 months
Phase 2b: OS
The OS was defined as the difference in days between the date of death and the first date of study treatment (+1 day).
Time frame: Up to approximately 6 years and 2 months
Phase 2b: DOR
The DOR was defined as the time from the first objective response (CR or PR) to the first documented PD per RECIST v1.1 or death from any cause, whichever occurred first. CR was defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm. PR was defined as at least 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters. PD: at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: Up to approximately 6 years and 2 months
Phase 2b: PSA50 DOR
The PSA50 DOR was defined as the time interval between the first date when PSA declined 50% or more from baseline and the date on which PSA progression was confirmed or death from any cause, whichever occurred first. PSA progression by PCWG3 criteria was defined as a PSA increase that was ≥ 25% and ≥ 2 ng/mL above the baseline or the nadir.
Time frame: Up to approximately 6 years and 2 months
Phase 2b: Duration of Stable Disease
Duration of stable disease by RECIST v1.1 was defined as the time interval between the first date when the criteria for stable disease were met and the first date on which objective progression was documented or death from any cause, whichever occurs first. Objective progression: at least a 20% increase in the SOD of target lesion. Stable disease was defined as \<30% decrease and \<20% increase in the size of target lesions, persistence of non-target lesions, and no new lesions.
Time frame: Up to approximately 6 years and 2 months
Phase 2a: Plasma Concentration of Talabostat
Time frame: Up to approximately 6 years and 2 months
Phase 2a: Concentration of Plasma Cytokines
Time frame: Up to approximately 6 years and 2 months
The study was conducted in United States from 10-Jun-2019 to 31-Aug-2025.
| Milestone | Phase 1B: Talabostat 0.4 mg QD + Pembrolizumab 200 mg | Phase 1B: Talabostat 0.6 mg QD + Pembrolizumab 200 mg | Phase 1B: Talabostat 0.6 mg TDD + Pembrolizumab 200 mg | Phase 2A (SCNC): Talabostat + Pembrolizumab 200 mg | Phase 2A (Adenocarcinoma): Talabostat + Pembrolizumab 200 mg | Phase 2B (Adenocarcinoma): Talabostat + Pembrolizumab 200 mg | Phase 2B (Adenocarcinoma): Talabostat Monotherapy |
|---|---|---|---|---|---|---|---|
| Started | 3 | 3 | 7 | 34 | 42 | 5 | 3 |
| Completed | 0 | 0 | 0 | 5 | 2 | 1 | 0 |
| Not completed | 3 | 3 | 7 | 29 | 40 | 4 | 3 |
| Withdrew: Death | 3 | 2 | 5 | 15 | 19 | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 1 | 1 | 4 | 12 | 1 | 1 |
| Withdrew: Protocol-defined disease progression | 0 | 0 | 1 | 0 | 3 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 2 | 2 | 0 | 0 |
| Withdrew: Other than specified | 0 | 0 | 0 | 8 | 3 | 3 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
CRR was defined as the percentage of participants who achieved 1 or more of the following: objective response by Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) criteria; ≥50% decline from baseline in serum Prostate-Specific Antigen (PSA); or Circulating Tumor Cell (CTC) conversion from ≥5/7.5 milliliters (mL) to \<5/7.5 mL per Veridex assay. Objective response rate was defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) among participants with evaluable lesions by RECIST v1.1. CR=disappearance of all target and non-target lesions and no new lesions. PR = ≥30% decrease in the sum of diameters (SOD) of target lesions compared to baseline and no new non-target lesion.
| percentage of participants | Phase 2A (SCNC): Talabostat + Pembrolizumab 200 mg | Phase 2A (Adenocarcinoma): Talabostat + Pembrolizumab 200 mg |
|---|---|---|
| Phase 2a: Composite Response Rate (CRR) | 20.0 (7.71 to 38.57) | 18.2 (6.98 to 35.46) |
The ORR was defined as the percentage of participants with a confirmed CR or PR among participants with evaluable lesions by RECIST v1.1. CR=disappearance of all target and non-target lesions and no new lesions. PR = ≥30% decrease in the sum of the diameters of target lesions compared to baseline and no new non-target lesion.
| percentage of participants | Phase 2B (Adenocarcinoma): Talabostat + Pembrolizumab 200 mg | Phase 2B (Adenocarcinoma): Talabostat Monotherapy |
|---|---|---|
| Phase 2b: Objective Response Rate (ORR) | 0.0 (0.00 to 70.76) | NA (NA to NA) |
The rPFS was defined as the time from the first dose to the date measurement criteria are first met for disease progression (PD) by RECIST 1.1/Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria or death from any cause, whichever occurred first. PD for soft tissue was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on study, including baseline, and an absolute increase of at least 5 millimeters (mm) in the SOD of target lesions; progression of non-target lesions; the appearance of one or more new lesions according to RECIST v1.1. PD for bone lesions was defined as 2 or more new lesions compared to baseline followed by a confirmatory bone scan at least 6 weeks later according to the PCWG3 criteria. Kaplan-Meier (KM) estimate was used to determine the median rPFS.
| months | Phase 2A (SCNC): Talabostat + Pembrolizumab 200 mg | Phase 2A (Adenocarcinoma): Talabostat + Pembrolizumab 200 mg |
|---|---|---|
| Phase 2a: Radiographic Progression-free Survival (rPFS) | 2.07 (1.91 to 4.17) | 1.87 (1.41 to 2.20) |
The PSA PFS was defined as the time from the date of first dose to the date measurement criteria were first met for PSA progression by PCWG3 criteria or death from any cause, whichever occurred first. PSA progression was defined as a PSA increase that was ≥ 25% and ≥ 2 nanograms (ng)/mL above the baseline or the nadir, which was confirmed by a second value ≥ 3 weeks later. KM estimate was used to determine the median PSA PFS.
| months | Phase 2A (SCNC): Talabostat + Pembrolizumab 200 mg | Phase 2A (Adenocarcinoma): Talabostat + Pembrolizumab 200 mg |
|---|---|---|
| Phase 2a: Prostate Specific Antigen (PSA) Progression-free Survival (PFS) | 10.94 (3.55 to 12.22) | 2.79 (1.45 to 7.98) |
The OS was defined as the difference in days between the date of death and the first date of study treatment (+1 day).
| months | Phase 2A (SCNC): Talabostat + Pembrolizumab 200 mg | Phase 2A (Adenocarcinoma): Talabostat + Pembrolizumab 200 mg |
|---|---|---|
| Phase 2a: Overall Survival (OS) | 13.67 (7.00 to NA) | 12.12 (5.45 to 16.36) |
The DOR was defined as the time from the first objective response (CR or PR) to the first documented PD per RECIST v1.1 or death from any cause, whichever occurred first. CR was defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm. PR was defined as at least 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters. PD: at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
| months | Phase 2A (SCNC): Talabostat + Pembrolizumab 200 mg | Phase 2A (Adenocarcinoma): Talabostat + Pembrolizumab 200 mg |
|---|---|---|
| Phase 2a: Duration of Response (DOR) | 9.03 (6.21 to NA) | NA (6.47 to NA) |
An adverse event (AE) was any untoward medical occurrence in a participant participating in a clinical investigation, whether or not considered related to treatment. A TEAE was defined as an AE occurring on / after the date of first dose of talabostat/pembrolizumab and within 30 days of the last dose of talabostat/pembrolizumab..
| Participants | Phase 2A (SCNC): Talabostat + Pembrolizumab 200 mg | Phase 2A (Adenocarcinoma): Talabostat + Pembrolizumab 200 mg |
|---|---|---|
| Phase 2a: Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 34 | 42 |
The PSA50 DOR was defined as the time interval between the first date when PSA declined 50% or more from baseline and the date on which PSA progression was confirmed or death from any cause, whichever occurred first. PSA progression by PCWG3 criteria was defined as a PSA increase that was ≥ 25% and ≥ 2 ng/mL above the baseline or the nadir.
| months | Phase 2A (SCNC): Talabostat + Pembrolizumab 200 mg | Phase 2A (Adenocarcinoma): Talabostat + Pembrolizumab 200 mg |
|---|---|---|
| Phase 2a: ≥50% Decline in PSA Value From Baseline (PSA50) Duration of Response (PSA50 DOR) | 14.75 (6.37 to NA) | NA (1.38 to NA) |
Duration of stable disease by RECIST v1.1 was defined as the time interval between the first date when the criteria for stable disease were met and the first date on which objective progression was documented or death from any cause, whichever occurs first. Objective progression: at least a 20% increase in the SOD of target lesion. Stable disease was defined as \<30% decrease and \<20% increase in the size of target lesions, persistence of non-target lesions, and no new lesions.
| months | Phase 2A (SCNC): Talabostat + Pembrolizumab 200 mg | Phase 2A (Adenocarcinoma): Talabostat + Pembrolizumab 200 mg |
|---|---|---|
| Phase 2a: Duration of Stable Disease | 3.12 (1.87 to NA) | 6.31 (2.33 to NA) |
| Participants | Phase 2B (Adenocarcinoma): Talabostat + Pembrolizumab 200 mg | Phase 2B (Adenocarcinoma): Talabostat Monotherapy |
|---|---|---|
| Phase 2b: Number of Participants With PSA Decline From Baseline of at Least 50% | 0 | 0 |
CRR was defined as the percentage of participants who achieved 1 or more of the following: objective response by RECIST v1.1 criteria; ≥50% decline from baseline in serum PSA, or CTC conversion from ≥5/7.5 mL to \<5/7.5 mL per Veridex assay. Objective response rate was defined as the percentage of participants with a confirmed CR or PR among participants with evaluable lesions by RECIST v1.1. CR=disappearance of all target and non-target lesions and no new lesions. PR = ≥30% decrease in the SOD of target lesions compared to baseline and no new non-target lesion.
| percentage of participants | Phase 2B (Adenocarcinoma): Talabostat + Pembrolizumab 200 mg | Phase 2B (Adenocarcinoma): Talabostat Monotherapy |
|---|---|---|
| Phase 2b: CRR | 0.0 (0.00 to 52.18) | 0.0 (0.00 to 84.19) |
The rPFS was defined as the time from the first dose to the date measurement criteria were first met for PD by RECIST 1.1/PCWG3 criteria or death from any cause, whichever occurred first. PD for soft tissue was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on study, including baseline, and an absolute increase of at least 5 mm in the SOD of target lesions; progression of non-target lesions; the appearance of one or more new lesions according to RECIST v1.1. PD for bone lesions was defined as 2 or more new lesions compared to baseline followed by a confirmatory bone scan at least 6 weeks later according to the PCWG3 criteria. KM estimate was used to determine the median rPFS.
| months | Phase 2B (Adenocarcinoma): Talabostat + Pembrolizumab 200 mg | Phase 2B (Adenocarcinoma): Talabostat Monotherapy |
|---|---|---|
| Phase 2b: rPFS | 1.38 (0.72 to NA) | 5.75 (0.95 to NA) |
The PSA PFS was defined as the time from the date of first dose to the date measurement criteria were first met for PSA progression by PCWG3 criteria or death from any cause, whichever occurred first. PSA progression was defined as a PSA increase that was ≥ 25% and ≥ 2 ng/mL above the baseline or the nadir. KM estimate was used to determine the median PSA PFS.
| percentage of participants | Phase 2B (Adenocarcinoma): Talabostat + Pembrolizumab 200 mg | Phase 2B (Adenocarcinoma): Talabostat Monotherapy |
|---|---|---|
| Phase 2b: PSA PFS | 1.41 (0.72 to NA) | 5.75 (0.95 to NA) |
The OS was defined as the difference in days between the date of death and the first date of study treatment (+1 day).
| months | Phase 2B (Adenocarcinoma): Talabostat + Pembrolizumab 200 mg | Phase 2B (Adenocarcinoma): Talabostat Monotherapy |
|---|---|---|
| Phase 2b: OS | NA (NA to NA) | 7.31 (4.07 to NA) |
The DOR was defined as the time from the first objective response (CR or PR) to the first documented PD per RECIST v1.1 or death from any cause, whichever occurred first. CR was defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm. PR was defined as at least 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters. PD: at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
| months | Phase 2B (Adenocarcinoma): Talabostat + Pembrolizumab 200 mg | Phase 2B (Adenocarcinoma): Talabostat Monotherapy |
|---|---|---|
| Phase 2b: DOR | NA (NA to NA) | NA (NA to NA) |
The PSA50 DOR was defined as the time interval between the first date when PSA declined 50% or more from baseline and the date on which PSA progression was confirmed or death from any cause, whichever occurred first. PSA progression by PCWG3 criteria was defined as a PSA increase that was ≥ 25% and ≥ 2 ng/mL above the baseline or the nadir.
| months | Phase 2B (Adenocarcinoma): Talabostat + Pembrolizumab 200 mg | Phase 2B (Adenocarcinoma): Talabostat Monotherapy |
|---|---|---|
| Phase 2b: PSA50 DOR | NA (NA to NA) | NA (NA to NA) |
Duration of stable disease by RECIST v1.1 was defined as the time interval between the first date when the criteria for stable disease were met and the first date on which objective progression was documented or death from any cause, whichever occurs first. Objective progression: at least a 20% increase in the SOD of target lesion. Stable disease was defined as \<30% decrease and \<20% increase in the size of target lesions, persistence of non-target lesions, and no new lesions.
| months | Phase 2B (Adenocarcinoma): Talabostat + Pembrolizumab 200 mg | Phase 2B (Adenocarcinoma): Talabostat Monotherapy |
|---|---|---|
| Phase 2b: Duration of Stable Disease | NA (2.20 to NA) | NA (NA to NA) |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Collected over From first dose of study drug up to approximately 6 years and 2 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1B: Talabostat 0.4 mg QD + Pembrolizumab 200 mg | 3/3 (100%) | 2/3 (66.7%) | 3/3 (100%) |
| Phase 1B: Talabostat 0.6 mg QD + Pembrolizumab 200 mg | 2/3 (66.7%) | 1/3 (33.3%) | 3/3 (100%) |
| Phase 1B: Talabostat 0.6 mg TDD + Pembrolizumab 200 mg | 5/7 (71.4%) | 4/7 (57.1%) | 7/7 (100%) |
| Phase 2A (SCNC): Talabostat + Pembrolizumab | 18/34 (52.9%) | 13/34 (38.2%) | 34/34 (100%) |
| Phase 2A (Adenocarcinoma): Talabostat + Pembrolizumab | 20/42 (47.6%) | 14/42 (33.3%) | 42/42 (100%) |
| Phase 2B (Adenocarcinoma): Talabostat + Pembrolizumab | 0/5 (0%) | 1/5 (20%) | 5/5 (100%) |
| Phase 2B (Adenocarcinoma): Talabostat Monotherapy | 2/3 (66.7%) | 1/3 (33.3%) | 3/3 (100%) |
| Event | Phase 1B: Talabostat 0.4 mg QD + Pembrolizumab 200 mg | Phase 1B: Talabostat 0.6 mg QD + Pembrolizumab 200 mg | Phase 1B: Talabostat 0.6 mg TDD + Pembrolizumab 200 mg | Phase 2A (SCNC): Talabostat + Pembrolizumab | Phase 2A (Adenocarcinoma): Talabostat + Pembrolizumab | Phase 2B (Adenocarcinoma): Talabostat + Pembrolizumab | Phase 2B (Adenocarcinoma): Talabostat Monotherapy |
|---|---|---|---|---|---|---|---|
| Urinary Tract InfectionInfections and infestations | 1/3 | 0/3 | 0/7 | 2/34 | 0/42 | 0/5 | 1/3 |
| SepsisInfections and infestations | 1/3 | 0/3 | 0/7 | 0/34 | 0/42 | 0/5 | 0/3 |
| AcidosisMetabolism and nutrition disorders | 0/3 | 1/3 | 0/7 | 0/34 | 0/42 | 0/5 | 0/3 |
| AnaemiaBlood and lymphatic system disorders | 1/3 | 0/3 | 0/7 | 0/34 | 1/42 | 0/5 | 0/3 |
| Malignant Neoplasm ProgressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/3 | 0/3 | 2/7 | 0/34 | 1/42 | 0/5 | 0/3 |
| Acute Kidney InjuryRenal and urinary disorders | 0/3 | 0/3 | 0/7 | 3/34 | 0/42 | 1/5 | 0/3 |
| Large Intestine PerforationGastrointestinal disorders | 0/3 | 0/3 | 1/7 | 0/34 | 0/42 | 0/5 | 0/3 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 0/3 | 0/3 | 1/7 | 0/34 | 0/42 | 0/5 | 0/3 |
| Back PainMusculoskeletal and connective tissue disorders | 0/3 | 0/3 | 1/7 | 1/34 | 1/42 | 0/5 | 0/3 |
| Abdominal PainGastrointestinal disorders | 0/3 | 0/3 | 1/7 | 1/34 | 1/42 | 0/5 | 0/3 |
| Event | Phase 1B: Talabostat 0.4 mg QD + Pembrolizumab 200 mg | Phase 1B: Talabostat 0.6 mg QD + Pembrolizumab 200 mg | Phase 1B: Talabostat 0.6 mg TDD + Pembrolizumab 200 mg | Phase 2A (SCNC): Talabostat + Pembrolizumab | Phase 2A (Adenocarcinoma): Talabostat + Pembrolizumab | Phase 2B (Adenocarcinoma): Talabostat + Pembrolizumab | Phase 2B (Adenocarcinoma): Talabostat Monotherapy |
|---|---|---|---|---|---|---|---|
| FatigueGeneral disorders | 3/3 | 1/3 | 3/7 | 16/34 | 24/42 | 1/5 | 0/3 |
| HypocalcaemiaMetabolism and nutrition disorders | 3/3 | 0/3 | 1/7 | 2/34 | 8/42 | 0/5 | 1/3 |
| ConstipationGastrointestinal disorders | 0/3 | 1/3 | 4/7 | 10/34 | 8/42 | 2/5 | 2/3 |
| Oedema PeripheralGeneral disorders | 2/3 | 2/3 | 0/7 | 12/34 | 5/42 | 2/5 | 0/3 |
| MyalgiaMusculoskeletal and connective tissue disorders | 1/3 | 2/3 | 1/7 | 3/34 | 5/42 | 1/5 | 0/3 |
| DizzinessNervous system disorders | 0/3 | 2/3 | 0/7 | 7/34 | 7/42 | 1/5 | 0/3 |
| Neuropathy PeripheralNervous system disorders | 2/3 | 0/3 | 1/7 | 1/34 | 0/42 | 0/5 | 0/3 |
| Blood Alkaline Phosphatase IncreasedInvestigations | 2/3 | 0/3 | 0/7 | 4/34 | 11/42 | 0/5 | 0/3 |
| AnaemiaBlood and lymphatic system disorders | 2/3 | 0/3 | 2/7 | 5/34 | 12/42 | 3/5 | 2/3 |
| Increased Tendency To BruiseBlood and lymphatic system disorders | 2/3 | 0/3 | 0/7 | 0/34 | 0/42 | 0/5 | 0/3 |
The safety population consisted of all participants who received any dose of talabostat or pembrolizumab during any phase of the study.
| Age, Categorical(Participants) | Phase 1B: Talabostat 0.4 mg QD + Pembrolizumab 200 mg | Phase 1B: Talabostat 0.6 mg QD + Pembrolizumab 200 mg | Phase 1B: Talabostat 0.6 mg TDD + Pembrolizumab 200 mg | Phase 2A (SCNC): Talabostat + Pembrolizumab | Phase 2A (Adenocarcinoma): Talabostat + Pembrolizumab 200 mg | Phase 2B (Adenocarcinoma): Talabostat + Pembrolizumab 200 mg | Phase 2B (Adenocarcinoma): Talabostat Monotherapy | Total |
|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 1 | 1 | 2 | 10 | 10 | 2 | 1 | 27 |
| >=65 years | 2 | 2 | 5 | 24 | 32 | 3 | 2 | 70 |
| Sex: Female, Male(Participants) | Phase 1B: Talabostat 0.4 mg QD + Pembrolizumab 200 mg | Phase 1B: Talabostat 0.6 mg QD + Pembrolizumab 200 mg | Phase 1B: Talabostat 0.6 mg TDD + Pembrolizumab 200 mg | Phase 2A (SCNC): Talabostat + Pembrolizumab | Phase 2A (Adenocarcinoma): Talabostat + Pembrolizumab 200 mg | Phase 2B (Adenocarcinoma): Talabostat + Pembrolizumab 200 mg | Phase 2B (Adenocarcinoma): Talabostat Monotherapy | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Male | 3 | 3 | 7 | 34 | 42 | 5 | 3 | 97 |
| Ethnicity (NIH/OMB)(Participants) | Phase 1B: Talabostat 0.4 mg QD + Pembrolizumab 200 mg | Phase 1B: Talabostat 0.6 mg QD + Pembrolizumab 200 mg | Phase 1B: Talabostat 0.6 mg TDD + Pembrolizumab 200 mg | Phase 2A (SCNC): Talabostat + Pembrolizumab | Phase 2A (Adenocarcinoma): Talabostat + Pembrolizumab 200 mg | Phase 2B (Adenocarcinoma): Talabostat + Pembrolizumab 200 mg | Phase 2B (Adenocarcinoma): Talabostat Monotherapy | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 2 | 0 | 2 | 1 | 5 |
| Not Hispanic or Latino | 2 | 3 | 7 | 32 | 40 | 3 | 2 | 89 |
| Unknown or Not Reported | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 3 |
| Race (NIH/OMB)(Participants) | Phase 1B: Talabostat 0.4 mg QD + Pembrolizumab 200 mg | Phase 1B: Talabostat 0.6 mg QD + Pembrolizumab 200 mg | Phase 1B: Talabostat 0.6 mg TDD + Pembrolizumab 200 mg | Phase 2A (SCNC): Talabostat + Pembrolizumab | Phase 2A (Adenocarcinoma): Talabostat + Pembrolizumab 200 mg | Phase 2B (Adenocarcinoma): Talabostat + Pembrolizumab 200 mg | Phase 2B (Adenocarcinoma): Talabostat Monotherapy | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 2 | 2 | 2 | 0 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 1 | 2 | 3 | 0 | 0 | 6 |
| White | 1 | 3 | 6 | 27 | 35 | 2 | 3 | 77 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Unknown or Not Reported | 2 | 0 | 0 | 3 | 2 | 0 | 0 | 7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2019 to primary completion in Oct 2023, 52 months.
Results were first posted in Nov 2026, 3 years after primary completion.
Of 96 industry-sponsored phase 1/2 interventional studies under Prostatic Neoplasms, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 35. This study's 52 months is close to that.
Counting every sponsor, half of 210 studies reached it within 61 months; a quarter within 30 and three quarters within 88.
Start moved once since we started tracking on Sep 25, 2026: Feb 2019 → Jun 2019, on Nov 10, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Phase 1B: Talabostat 0.4 mg QD + Pembrolizumab 200 mg · Phase 1B: Talabostat 0.6 mg QD + Pembrolizumab 200 mg · Phase 1B: Talabostat 0.6 mg TDD + Pembrolizumab 200 mg · Phase 2A (SCNC): Talabostat + Pembrolizumab 200 mg · Phase 2A (Adenocarcinoma): Talabostat + Pembrolizumab 200 mg · Phase 2B (Adenocarcinoma): Talabostat + Pembrolizumab 200 mg
Phase 1B: Talabostat 0.4 mg QD + Pembrolizumab 200 mg · Phase 1B: Talabostat 0.6 mg QD + Pembrolizumab 200 mg · Phase 1B: Talabostat 0.6 mg TDD + Pembrolizumab 200 mg · Phase 2A (SCNC): Talabostat + Pembrolizumab 200 mg · Phase 2A (Adenocarcinoma): Talabostat + Pembrolizumab 200 mg · Phase 2B (Adenocarcinoma): Talabostat + Pembrolizumab 200 mg
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Talabostat
BioXcel Therapeutics Inc